Lofland JH - Search Results

1

Systemic Lupus Erythematosus Symptom Clusters and Their Association With Patient-Reported Outcomes and Treatment: Analysis of Real-World Data.

Touma Z, Hoskin B, Atkinson C, Bell D, Massey O, Lofland JH, Berry P, Karyekar CS, Costenbader KH. Touma Z, et al. Among authors: lofland jh. Arthritis Care Res (Hoboken). 2022 Jul;74(7):1079-1088. doi: 10.1002/acr.24546. Epub 2022 Apr 22. Arthritis Care Res (Hoboken). 2022. PMID: 33345456

2

Real-world impact of flaring on patient-reported outcomes and healthcare resource utilisation in systemic lupus erythematosus.

Costenbader KH, Hoskin B, Atkinson C, Bell D, Pike J, Lofland JH, Berry P, Karyekar CS, Touma Z. Costenbader KH, et al. Among authors: lofland jh. Clin Exp Rheumatol. 2022 Nov;40(11):2023-2031. doi: 10.55563/clinexprheumatol/k9yyeq. Epub 2021 Dec 10. Clin Exp Rheumatol. 2022. PMID: 34905485 Free article.

3

Update on prevalence of diagnosed systemic lupus erythematosus (SLE) by major health insurance types in the US in 2016.

Wang Y, Hester LL, Lofland J, Rose S, Karyekar CS, Kern DM, Blacketer M, Davis K, Shields-Tuttle K. Wang Y, et al. BMC Res Notes. 2022 Jan 9;15(1):5. doi: 10.1186/s13104-021-05877-1. BMC Res Notes. 2022. PMID: 35000586 Free PMC article.

4

Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus.

Kedves M, Kósa F, Kunovszki P, Takács P, Szabó MZ, Karyekar C, Lofland JH, Nagy G. Kedves M, et al. Among authors: lofland jh. Rheumatology (Oxford). 2020 Nov 1;59(11):3443-3451. doi: 10.1093/rheumatology/keaa188. Rheumatology (Oxford). 2020. PMID: 32357240 Free PMC article.

5

Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States.

Kariburyo F, Xie L, Sah J, Li N, Lofland JH. Kariburyo F, et al. Among authors: lofland jh. J Med Econ. 2020 Jan;23(1):1-9. doi: 10.1080/13696998.2019.1678170. Epub 2019 Oct 21. J Med Econ. 2020. PMID: 31589081 Free article.

6

Inadequate Disease Control, Treatment Dissatisfaction, and Quality-of-Life Impairments Among US Patients Receiving Topical Therapy for Atopic Dermatitis.

Anderson P, Austin J, Lofland JH, Piercy J, Joish VN. Anderson P, et al. Among authors: lofland jh. Dermatol Ther (Heidelb). 2021 Oct;11(5):1571-1585. doi: 10.1007/s13555-021-00580-2. Epub 2021 Jul 15. Dermatol Ther (Heidelb). 2021. PMID: 34268709 Free PMC article.

7

Variations in care: a retrospective database analysis of healthcare utilization patterns for patients with inflammatory bowel disease.

David G, Gunnarsson C, Lofland JH. David G, et al. Among authors: lofland jh. J Med Econ. 2015 Feb;18(2):137-44. doi: 10.3111/13696998.2014.978454. Epub 2014 Oct 30. J Med Econ. 2015. PMID: 25335098 Free article.

8

Cost-per-remission analysis of infliximab compared to adalimumab among adults with moderate-to-severe ulcerative colitis.

Lofland JH, Mallow P, Rizzo J. Lofland JH, et al. J Med Econ. 2013;16(4):461-7. doi: 10.3111/13696998.2013.775134. Epub 2013 Feb 27. J Med Econ. 2013. PMID: 23445401 Free article.

9

Adjusting for comorbidities in cost of illness studies.

Rizzo JA, Chen J, Gunnarsson CL, Naim A, Lofland JH. Rizzo JA, et al. Among authors: lofland jh. J Med Econ. 2015 Jan;18(1):12-28. doi: 10.3111/13696998.2014.969434. Epub 2014 Oct 9. J Med Econ. 2015. PMID: 25253504 Free article.

10

Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis.

Han C, Lofland JH, Zhao N, Schenkel B. Han C, et al. Among authors: lofland jh. J Drugs Dermatol. 2011 Aug;10(8):843-50. J Drugs Dermatol. 2011. PMID: 21818505

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

48 results

Search Page

Filters